These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1362 related items for PubMed ID: 25227313

  • 1. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies.
    Thal DR, Attems J, Ewers M.
    J Alzheimers Dis; 2014; 42 Suppl 4():S421-9. PubMed ID: 25227313
    [Abstract] [Full Text] [Related]

  • 2. Alzheimer's disease.
    De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [Abstract] [Full Text] [Related]

  • 3. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
    Koss DJ, Jones G, Cranston A, Gardner H, Kanaan NM, Platt B.
    Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
    [Abstract] [Full Text] [Related]

  • 4. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease.
    Prvulovic D, Hampel H.
    Clin Chem Lab Med; 2011 Mar; 49(3):367-74. PubMed ID: 21342022
    [Abstract] [Full Text] [Related]

  • 5. Regional White Matter Hyperintensities and Alzheimer's Disease Biomarkers Among Older Adults with Normal Cognition and Mild Cognitive Impairment.
    Newton P, Tchounguen J, Pettigrew C, Lim C, Lin Z, Lu H, Moghekar A, Albert M, Soldan A, BIOCARD Research Team.
    J Alzheimers Dis; 2023 Mar; 92(1):323-339. PubMed ID: 36744337
    [Abstract] [Full Text] [Related]

  • 6. Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging.
    Maass A, Lockhart SN, Harrison TM, Bell RK, Mellinger T, Swinnerton K, Baker SL, Rabinovici GD, Jagust WJ.
    J Neurosci; 2018 Jan 17; 38(3):530-543. PubMed ID: 29192126
    [Abstract] [Full Text] [Related]

  • 7. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
    Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, Joshi AD, Devous MD, Mintun MS.
    Brain; 2016 May 17; 139(Pt 5):1539-50. PubMed ID: 26936940
    [Abstract] [Full Text] [Related]

  • 8. Olfactory tau pathology in Alzheimer disease and mild cognitive impairment.
    Attems J, Jellinger KA.
    Clin Neuropathol; 2006 May 17; 25(6):265-71. PubMed ID: 17140156
    [Abstract] [Full Text] [Related]

  • 9. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
    Watanabe H.
    Yakugaku Zasshi; 2017 May 17; 137(11):1361-1365. PubMed ID: 29093372
    [Abstract] [Full Text] [Related]

  • 10. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
    Koychev I, Hofer M, Friedman N.
    J Nucl Med; 2020 Oct 17; 61(10):1413-1418. PubMed ID: 32764121
    [Abstract] [Full Text] [Related]

  • 11. Molecular imaging of dementia.
    Mori T, Maeda J, Shimada H, Higuchi M, Shinotoh H, Ueno S, Suhara T.
    Psychogeriatrics; 2012 Jun 17; 12(2):106-14. PubMed ID: 22712644
    [Abstract] [Full Text] [Related]

  • 12. Tau pathology-dependent remodelling of cerebral arteries precedes Alzheimer's disease-related microvascular cerebral amyloid angiopathy.
    Merlini M, Wanner D, Nitsch RM.
    Acta Neuropathol; 2016 May 17; 131(5):737-52. PubMed ID: 26988843
    [Abstract] [Full Text] [Related]

  • 13. Alzheimer's disease and amyloid: culprit or coincidence?
    Skaper SD.
    Int Rev Neurobiol; 2012 May 17; 102():277-316. PubMed ID: 22748834
    [Abstract] [Full Text] [Related]

  • 14. The Brain's Structural Connectome Mediates the Relationship between Regional Neuroimaging Biomarkers in Alzheimer's Disease.
    Pandya S, Kuceyeski A, Raj A, Alzheimer’s Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2017 May 17; 55(4):1639-1657. PubMed ID: 27911289
    [Abstract] [Full Text] [Related]

  • 15. Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers.
    Chételat G, Fouquet M.
    Rev Neurol (Paris); 2013 Oct 17; 169(10):729-36. PubMed ID: 24016463
    [Abstract] [Full Text] [Related]

  • 16. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
    de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Clark C, Kerkman D, DeBernardis J, Li J, Lair L, Reisberg B, Tsui W, Rusinek H.
    J Intern Med; 2004 Sep 17; 256(3):205-23. PubMed ID: 15324364
    [Abstract] [Full Text] [Related]

  • 17. Pathology of clinical and preclinical Alzheimer's disease.
    Thal DR, von Arnim C, Griffin WS, Yamaguchi H, Mrak RE, Attems J, Upadhaya AR.
    Eur Arch Psychiatry Clin Neurosci; 2013 Nov 17; 263 Suppl 2():S137-45. PubMed ID: 24077890
    [Abstract] [Full Text] [Related]

  • 18. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
    Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, De Leenheir E, Martin JJ, Vanmechelen E, Van Broeckhoven C, De Deyn PP.
    Brain; 2007 Sep 17; 130(Pt 9):2320-6. PubMed ID: 17586559
    [Abstract] [Full Text] [Related]

  • 19. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
    Oddo S, Caccamo A, Cheng D, Jouleh B, Torp R, LaFerla FM.
    J Neurochem; 2007 Aug 17; 102(4):1053-63. PubMed ID: 17472708
    [Abstract] [Full Text] [Related]

  • 20. Typical and atypical appearance of early-onset Alzheimer's disease: A clinical, neuroimaging and neuropathological study.
    Kawakatsu S, Kobayashi R, Hayashi H.
    Neuropathology; 2017 Apr 17; 37(2):150-173. PubMed ID: 28093855
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 69.